Biotech News

OraSure Announces Third Quarter 2026 Financial Results; Strategic Execution Drives Double-Digit Year-Over-Year Growth and Margin Expansion

OraSure Technologies, Inc. (OSUR)OraSure Technologies, Inc.Earnings

14% year-over-year revenue growth in the quarter highlights effectiveness of return-to-growth strategy GAAP gross margin improved by over 170 bps vs. prior year to 45.2% Received initial orders of Colli-Pee®•Dx and OraQuick® Ebola 2.0 in the quarter OTI expects an acceleration of full-year revenue

Related news

OraSure Technologies, Inc.

Decentralized Diagnostics OraSure Technologies develops point-of-need and at-home diagnostic tests intended to make testing more accessible, private and convenient. Rapid-Test Portfolio The company's products cover infectious diseases and other conditions across consumer, clinical, public-health and community settings. Subsidiaries...

Recent company news

Stock data

Close
3.61 USD
Market cap
275.39M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States